Sandoz US News and Activities

Sandoz US is owned by Sandoz.

Sandoz is one of the...

• Forbes Global 2000 (#939);
• TOB Iconic 10,000.

Sandoz is a company listed under the stock ticker SDZNY (DE).

Sandoz has a direct presence in 18 countries.

Sandoz has 19 subsidiaries including Lek, Sandoz Asia and Sandoz Austria.

View the org chart displaying its 18 main executives

Most searched biographies at Sandoz US

• Keren Haruvi, President
• Enrique Linero, Mexico, Andean Region, Central America and the Car...
• Mohammed Obeidat, Vice President and Chief Financial Officer

Popular executive movements at Sandoz US

• Nimish Muzumdar, Vice President, Products & Retail, has left the company  (posted on June 17 2026).
• Enrique Linero, who was General Manager of Mexico, Central America and Caribbean, is promoted to Mexico, Andean Region, Central America and the Caribbean  (posted on May 11 2026).

Popular executive movements at Sandoz

• Keren Haruvi who is President, North America, will be promoted to Head of Global Mergers and Acquisitions President of North America on Aug. 1, 2026  (posted on July 16 2026).
• Pascal Bouye will join the company as President, Generics Manufacturing and Supply Member of the Executive Committee on Aug. 20, 2026  (posted on July 16 2026).
• Armin Metzger will join the company as President of Biosimilars Development, Manufacturing and Supply on Apr. 1, 2026  (posted on March 27 2026).

Click here to view some more movements at Sandoz

Create your alert
to follow the executive moves at Sandoz US.

Sandoz has 1,919 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• Agenus has just announced a $340 Million fundraising (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Richard Saynor - Chief Executive Officer at Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson

Learn more about the Pharmaceuticals industry

Press releases by Sandoz US

• FDA approves Tyruko® (natalizumab-sztn), the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis | Sandoz US
• Sandoz AG expands reach of adalimumab biosimilar in US through commercialization agreement with Cordavis | Sandoz US
• Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis | Sandoz US
• Hyrimoz® (adalimumab-adaz) high-concentration formulation now available in the US | Sandoz US
• Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space | Sandoz US
• Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines | Sandoz US
• Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines | Sandoz US
• Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation | Sandoz US
• Engaging with Critical Stakeholders at the 2023 National Health Council’s Leadership Conference | Sandoz US
• Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA | Sandoz US
• View more press releases Close

Social media about Sandoz US

• Sandoz US on Wikipedia, Google News & Yahoo Finance
• Sandoz US on LinkedIn, X (Twitter) & YouTube